Geneva, July 20 -- International Clinical Trials Registry received information related to the study (ISRCTN72157798) titled 'Developing a vaccine against Bundibugyo ebolavirus' on July 13.
Study Type: Interventional
Study Design:
Allocation: Randomized controlled trial
Masking: Blinded (masking used)
Control: Placebo
Assignment: Single
Purpose: Prevention
Primary Sponsor: University of Oxford
Condition:
Bundibugyo ebolavirus
Infections and Infestations
Intervention:
This is a first-in-human Phase Ia trial to assess the safety, tolerability, and immunogenicity of the ChAdOx1 Ebola BDBV Vaccine (Recombinant) in healthy volunteers aged 18-55 years. The trial will consist of two phases.
In phase A, an initial open-label cohort (coho...